UB Paderborn / Katalog / Suche / in CDI

Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives

Cancers, 2020-12, Vol.13 (1), p.47

2020

Volltextzugriff (PDF)

Epidemiology, risk factors, and prognostic factors of gliomas

Clinical and translational imaging : reviews in nuclear medicine and molecular imaging, 2022, Vol.10 (5), p.467-475

2022

Volltextzugriff (PDF)

Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study

Cancers, 2021-09, Vol.13 (18), p.4731

2021

Volltextzugriff (PDF)

Clinical Management of Diffuse Low-Grade Gliomas

Cancers, 2020-10, Vol.12 (10), p.3008

2020

Volltextzugriff (PDF)

Diagnosis and Treatment of Pineal Region Tumors in Adults: A EURACAN Overview

Cancers, 2022-08, Vol.14 (15), p.3646

2022

Volltextzugriff (PDF)

The role of radiation therapy and systemic treatments in meningioma: The present and the future

Cancer medicine (Malden, MA), 2023-08, Vol.12 (15), p.16041-16053

2023

Volltextzugriff (PDF)

Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO)

Cancers, 2021-06, Vol.13 (11), p.2773

2021

Volltextzugriff (PDF)

Newly Diagnosed Multifocal GBM: A Monocentric Experience and Literature Review

Current oncology (Toronto), 2022-05, Vol.29 (5), p.3472-3488

2022

Volltextzugriff (PDF)

Efficacy and safety of chlorpromazine as an adjuvant therapy for glioblastoma in patients with unmethylated MGMT gene promoter: RACTAC, a phase II multicenter trial

Frontiers in oncology, 2023, Vol.13, p.1320710-1320710

2023

Volltextzugriff (PDF)

Spinal ependymoma in adults: from molecular advances to new treatment perspectives

Frontiers in oncology, 2023, Vol.13, p.1301179-1301179

2023

Volltextzugriff (PDF)

An Overview of Intracranial Ependymomas in Adults

Cancers, 2021-12, Vol.13 (23), p.6128

2021

Volltextzugriff (PDF)

Regorafenib in recurrent glioblastoma patients: A large real-life experience

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e14024-e14024

2021

Volltextzugriff (PDF)

CTNI-50. REGORAFENIB IN RECURRENT GLIOBLASTOMA PATIENTS: A LARGE REAL-LIFE EXPERIENCE

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Supplement_6), p.vi71-vi71

2021

Volltextzugriff (PDF)

Impressive response to dabrafenib and trametinib plus silybin in a heavily pretreated IDH wild-type glioblastoma patient with BRAFV600E -mutant and SOX2 amplification

Anti-cancer drugs, 2023-01, Vol.34 (1), p.190

2023

Volltextzugriff (PDF)

ANGI-09. BEVACIZUMAB IN ATYPICAL AND ANAPLASTIC MENINGIOMAS: THE BEMEN STUDY

Neuro-oncology (Charlottesville, Va.), 2022-11, Vol.24 (Supplement_7), p.vii3-vii3

2022

Volltextzugriff (PDF)

Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis

European journal of cancer (1990), 2023-09, Vol.191, p.112959-112959, Article 112959

2023

Volltextzugriff (PDF)

Present and Future of Immunotherapy in Patients With Glioblastoma: Limitations and Opportunities

The oncologist (Dayton, Ohio), 2024-04, Vol.29 (4), p.289-302

2024

Volltextzugriff (PDF)

CTNI-33. METRONOMIC TEMOZOLOMIDE THERAPY IN HEAVILY PRETREATED PATIENTS WITH RECURRENT GLIOBLASTOMA: A LARGE MONO-INSTITUTIONAL RETROSPECTIVE STUDY

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Suppl 6), p.vi66-vi67

2021

Volltextzugriff (PDF)

CTNI-33. METRONOMIC TEMOZOLOMIDE THERAPY IN HEAVILY PRETREATED PATIENTS WITH RECURRENT GLIOBLASTOMA: A LARGE MONO-INSTITUTIONAL RETROSPECTIVE STUDY

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Supplement_6), p.vi66-vi67

2021

Volltextzugriff (PDF)

Decoding the puzzle: A multidisciplinary systematic review of adult brainstem glioma

Critical reviews in oncology/hematology, 2024-04, Vol.196, p.104261, Article 104261

2024

Volltextzugriff (PDF)

The clinical significance of telomerase reverse transcriptase ( TERT ) promoter mutations, telomere length and O6-methylguanine DNA methyltransferase ( MGMT ) promoter methylation status in newly diagnosed and recurrent IDH -wildtype glioblastoma (GBM) patients (PTS): A large mono-institutional study

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2053-2053

2021

Volltextzugriff (PDF)

Next-generation sequencing (NGS) for identifying actionable molecular alterations in patients with newly diagnosed and recurrent IDHwt-glioblastoma (GBM): A large mono-institutional experience

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3139-3139

2022

Volltextzugriff (PDF)

Phase II multicentric Italian trial on repositioning of the antipsychotic drug chlorpromazine and its combination with temozolomide in patients with MGMT unmethylated glioblastoma: The RACTAC trial

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS2073-TPS2073

2022

Volltextzugriff (PDF)

CTNI-38. RACTAC TRIAL: PHASE II MULTICENTRIC ITALIAN TRIAL ON REPOSITIONING OF THE ANTIPSYCHOTIC DRUG CHLORPROMAZINE AND ITS COMBINATION WITH TEMOZOLOMIDE IN MGMT UNMETHYLATED GLIOBLASTOMA PATIENTS

Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v83-v83

2023

Volltextzugriff (PDF)

BIOM-21. THE SIGNIFICANCE OF TERT PROMOTER MUTATIONS, TELOMERE LENGTH AND MGMT PROMOTER METHYLATION IN NEWLY DIAGNOSED AND RECURRENT IDH-WILDTYPE GLIOBLASTOMA (GBM): A LARGE MONO-INSTITUTIONAL STUDY

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Supplement_6), p.vi15-vi15

2021

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives

Epidemiology, risk factors, and prognostic factors of gliomas

Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study

Clinical Management of Diffuse Low-Grade Gliomas

Diagnosis and Treatment of Pineal Region Tumors in Adults: A EURACAN Overview

The role of radiation therapy and systemic treatments in meningioma: The present and the future

Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO)

Newly Diagnosed Multifocal GBM: A Monocentric Experience and Literature Review

Efficacy and safety of chlorpromazine as an adjuvant therapy for glioblastoma in patients with unmethylated MGMT gene promoter: RACTAC, a phase II multicenter trial

Spinal ependymoma in adults: from molecular advances to new treatment perspectives

An Overview of Intracranial Ependymomas in Adults

Regorafenib in recurrent glioblastoma patients: A large real-life experience

CTNI-50. REGORAFENIB IN RECURRENT GLIOBLASTOMA PATIENTS: A LARGE REAL-LIFE EXPERIENCE

Impressive response to dabrafenib and trametinib plus silybin in a heavily pretreated IDH wild-type glioblastoma patient with BRAFV600E -mutant and SOX2 amplification

ANGI-09. BEVACIZUMAB IN ATYPICAL AND ANAPLASTIC MENINGIOMAS: THE BEMEN STUDY

Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis

Present and Future of Immunotherapy in Patients With Glioblastoma: Limitations and Opportunities

CTNI-33. METRONOMIC TEMOZOLOMIDE THERAPY IN HEAVILY PRETREATED PATIENTS WITH RECURRENT GLIOBLASTOMA: A LARGE MONO-INSTITUTIONAL RETROSPECTIVE STUDY

CTNI-33. METRONOMIC TEMOZOLOMIDE THERAPY IN HEAVILY PRETREATED PATIENTS WITH RECURRENT GLIOBLASTOMA: A LARGE MONO-INSTITUTIONAL RETROSPECTIVE STUDY

Decoding the puzzle: A multidisciplinary systematic review of adult brainstem glioma

Next-generation sequencing (NGS) for identifying actionable molecular alterations in patients with newly diagnosed and recurrent IDHwt-glioblastoma (GBM): A large mono-institutional experience

Phase II multicentric Italian trial on repositioning of the antipsychotic drug chlorpromazine and its combination with temozolomide in patients with MGMT unmethylated glioblastoma: The RACTAC trial

CTNI-38. RACTAC TRIAL: PHASE II MULTICENTRIC ITALIAN TRIAL ON REPOSITIONING OF THE ANTIPSYCHOTIC DRUG CHLORPROMAZINE AND ITS COMBINATION WITH TEMOZOLOMIDE IN MGMT UNMETHYLATED GLIOBLASTOMA PATIENTS

BIOM-21. THE SIGNIFICANCE OF TERT PROMOTER MUTATIONS, TELOMERE LENGTH AND MGMT PROMOTER METHYLATION IN NEWLY DIAGNOSED AND RECURRENT IDH-WILDTYPE GLIOBLASTOMA (GBM): A LARGE MONO-INSTITUTIONAL STUDY

Suchergebnisse filtern